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Background: The	antiphospholipid	syndrome	 (APS)	 is	characterized	by	 thrombosis	







patients	 and	 controls.	Anti‐CL	and	aβ2GPI	 IgG	and	 IgM	antibodies	were	detected	
with	four	commercially	available	solid	phase	assays.
Results: Positivity	for	aCL	and/or	aβ2GPI	antibodies	was	significantly	correlated	with	









of	obstetric	APS.	However,	 no	 added	value	was	 found	 for	 testing	 IgM	 in	patients	
suspected	of	thrombotic	APS.	Still,	IgM	aPL	might	be	useful	as	a	second‐line	test	to	
improve	thrombotic	risk	stratification.
K E Y W O R D S
antiphospholipid	antibodies,	immunoassays,	immunoglobulin	isotypes,	pregnancy	morbidity,	
thrombosis
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1  | INTRODUC TION
The	 antiphospholipid	 syndrome	 (APS)	 is	 characterized	 by	 throm‐
bosis	 and/or	pregnancy	morbidity	with	 the	persistent	presence	of	
antiphospholipid	 antibodies	 (aPL).1	 Obstetrical	 complications	 in‐
clude	 fetal	 loss	 after	 the	 10th	 week	 of	 gestation,	 recurrent	 early	
miscarriages	 and	 premature	 birth	 due	 to	 severe	 preeclampsia,	 or	
intrauterine growth restriction.1	 Thrombotic	 APS	 is	 characterized	
by	 venous,	 arterial,	 and/or	 small	 vessel	 thrombosis.1	 Diagnosis	 of	
APS	predominantly	relies	on	aPL	assays	detecting	lupus	anticoagu‐
lant	(LAC)	by	a	functional	assay	or	detection	of	anti‐cardiolipin	(aCL)	


















as	 a	 single	 serologic	marker,	 because	 of	 unavailability	 of	 separate	

























Patient	 samples	were	 collected	 from	 eight	 European	medical	 cent‐
ers	within	a	time	span	of	one	year,	with	patient	samples	stored	less	
than	five	years	at	or	below	‐80°C.	The	Sydney	classification	criteria	










severe	preeclampsia	defined	according	 to	 standard	definitions,	 rec‐
ognized	 features	of	placental	 insufficiency;	 (3)	 three	or	more	unex‐






without	 thrombotic	 complications	 (autoimmune	 disease	 [AID]	 con‐
trols);	patients	 that	were	 referred	 for	aPL	 testing	 for	other	 reasons	
than	 the	clinical	criteria	of	APS	 (eg,	 subfertility	and	prolonged	acti‐
vated	partial	 thromboplastin	 time	 [aPTT],	 controls);	 patients	with	 a	
previous	thrombotic	event	negatively	tested	for	aPL	(non‐APS	throm‐
bosis);	 and	patients	 that	experienced	obstetric	complications	 in	 the	
absence	of	aPL	(non‐APS	obstetric).	The	study	was	approved	by	the	
local ethical committees.
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Laboratories,	 Bedford,	 USA)	 and	 QUANTA	 Lite®	 ELISA	 (Inova	
Diagnostics,	 San	 Diego,	 USA)	 in	 the	 Ghent	 University	 Hospital	
(Ghent,	Belgium).	Detection	of	aCL	and	aβ2GPI	antibodies	was	per‐
formed	 according	 to	 manufacturer's	 instructions.	 Manufacturer's	




thrombotic	 APS,	 non‐APS	 thrombosis,	 AID	 controls,	 and	 controls.	





with variables having a P‐value	<	0.2.	In	order	to	evaluate	independent	
variables	for	thrombosis,	analysis	was	performed	on	the	total	popula‐
tion	with	a	model	including	age,	sex,	pregnancy	morbidity,	LAC,	IgG,	


















































































































































































































































































































































































(5%),	 and	 direct	 oral	 anticoagulants	 (4%).	 Twenty‐seven	 patients	
(10%)	received	antiplatelet	therapy	and	2%	of	patients	with	throm‐
botic	 APS	 received	 both	 anticoagulant	 and	 antiplatelet	 therapy.	
Details	on	anticoagulant	and	antiplatelet	 therapy	of	 the	 remaining	
84	patients	were	not	available.
4.2 | Diagnostic role of aCL and aβ2GPI IgG/IgM 
antibodies in thrombosis
Lupus	 anticoagulant	 positivity	 resulted	 in	 an	 odds	 ratio	 (OR)	 for	





antibodies	 (Table	2).	 Lupus	 anticoagulant,	 IgG	 aCL	or	 aβ2GPI,	 and	
IgM	aCL	or	aβ2GPI	were	analyzed	in	a	multivariate	model	in	which	










4.3 | Diagnostic role of aCL and aβ2GPI IgG/IgM 






tibodies	 (Table	3).	 In	 contrast	 to	 thrombosis,	 IgM	aCL	or	aβ2GPI	
antibodies	 was	 an	 independent	 variable	 for	 pregnancy	 morbid‐
ity	with	OR	 ranging	between	1.7	 (95%	CI,	 1.1‐2.8)	 and	2.0	 (95%	
CI,	 1.1‐3.5).	 The	OR	 of	 LAC	 positivity	 varied	 between	 3.6	 (95%	
CI,2.3‐5.7)	and	3.9	(95%	CI,	2.5‐6.1)	(Table	3).	IgG	aCL	or	aβ2GPI	
antibodies	was	an	independent	variable	with	three	out	of	the	four	
tested	 solid	 phase	 assays,	 resulting	 in	OR	between	1.9	 (95%	CI,	
1.1‐3.2)	and	2.5	(95%	CI,	1.5‐4.4).
4.4 | Additional diagnostic value of aCL and aβ2GPI 
IgM antibodies in thrombotic patients




























































































































































































































































































































































































































































4.5 | Additional diagnostic value of aCL and aβ2GPI 















solid	 phase	 assay.	No	 significant	 difference	 in	 IgM	 aCL	 or	 aβ2GPI	
antibody	 titers	 was	 found	 between	 patients	 with	 thrombosis	 and	
our	control	population	with	the	exception	of	one	solid	phase	assay	
(Phadia®)	(Figure	1A).









4.8 | Additional clinical value of aCL and aβ2GPI I 
IgM antibodies in thrombotic patients
Within	the	current	criteria	positivity	for	either	LAC,	IgG	aCL/aβ2GPI,	
or	IgM	aCL/aβ2GPI	is	sufficient	for	classification	of	APS.	In	our	co‐
hort,	 these	classification	criteria	 resulted	 in	OR	between	2.4	 (95%	
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with	two	out	of	the	four	tested	solid	phase	assays.	With	the	other	









4.9 | Additional clinical value of aCL and aβ2GPI 





















The	 role	 of	 IgM	aCL	or	 aβ2GPI	 antibodies	 as	 a	 serologic	marker	










ent	variable	 for	 thrombosis.	 In	 addition,	 IgM	aCL	or	 aβ2GPI	was	






been	 reported	 in	 literature.	One	study	concluded	 that	 “isolated”	
IgG	antibodies	are	more	prevalent	in	deep	venous	thrombosis	and	
pulmonary	 embolism	 while	 “isolated”	 aCL	 IgM	 antibodies	 were	
frequently	 found	 in	patients	with	 a	 cerebrovascular	 infarction.23 
However,	patients	were	only	tested	for	aCL	and	aβ2GPI	IgG/IgM	
antibodies	 and	 not	 for	 LAC,	 rendering	 the	 identification	 of	 true	
isolated	 IgG	 or	 IgM	 antibodies	 impossible.23 While we showed 




Within	 the	current	 aPL‐panel,	 LAC	 is	 considered	 the	 strongest	
predictor	 of	 thrombosis	 and	 pregnancy	 morbidity.25,26	 In	 2003,	
a	 meta‐analysis	 assessed	 the	 role	 of	 LAC	 and	 aCL	 antibodies	 in	























































































dependent	 manner.1,3,27‐29	 A	 more	 recent	 meta‐analysis	 included	
studies	 between	2001	 and	2014	 and	 showed	 that	 aCL	 antibodies	










IgG/IgM	 antibodies	 were	 found	 to	 be	 independently	 associated	
with	pregnancy	morbidity.	In	contrast,	IgM	was	not	independently	
associated	 with	 thrombosis.	 In	 agreement,	 a	 systematic	 review	
and	meta‐analysis	found	a	significant	association	of	LAC,	aCL	IgG/
IgM,	and	aβ2GPI	 IgG/IgM	antibodies	with	preeclampsia	and	fetal	
death.31	 Another	 study	 found	 that	 positivity	 for	 LAC,	 aCL	 IgG,	
and	aCL	 IgM	were	associated	with	 recurrent	 fetal	 loss	 in	women	
without autoimmune disease.6	 In	 the	 same	 study,	 no	 significant	
association	 was	 found	 between	 aβ2GPI	 positivity	 and	 recurrent	
loss,	presumably	due	to	the	small	study	population.6	 In	a	popula‐
tion‐based,	case‐control	study,	aPL	were	measured	in	582	stillbirth	
deliveries and 1547 live birth deliveries.32 Women with a stillbirth 
were	 found	 to	 be	more	 likely	 to	 have	 elevated	 aCL	 and	 aβ2GPI	
IgG	levels,	but	not	aCL	and	aβ2GPI	IgM	levels	compared	to	those	
with term live births.32	We	found	a	significant	association	between	
aCL	 IgM	or	aβ2GPI	 IgM	antibodies	and	pregnancy	morbidity,	but	




shown	 that	 LAC	 is	 the	 primary	 predictor	 of	 obstetric	 complica‐
tions	after	12	weeks	of	gestation	in	aPL	associated	pregnancies.25 
TA B L E  4  Additional	diagnostic	value	of	aCL	and	aβ2GPI	IgM	antibodies
  
Overall popula‐










(n = 122) AID (n = 196)
Controls 
(n = 194)
LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG
A
  + − + − + − + − + − + − + −
IgM + 95 23 0 0 58 9 0 0 19 7 12 6 6 1
 − 304 586 3 201 157 35 0 33 72 24 56 122 16 171
Total  399 609 3 201 215 44 0 33 91 31 68 128 22 172
B
  + − + − + − + − + − + − + −
IgM + 135 72 2 5 80 14 1 2 30 12 15 25 7 14
 − 273 528 10 187 136 29 1 29 62 18 51 105 13 160
Total  408 600 12 192 216 43 2 31 92 30 66 130 20 174
C
  + − + − + − + − + − + − + −
IgM + 123 37 0 1 71 10 0 1 24 9 21 10 7 6
 − 294 554 7 196 153 25 0 32 70 19 50 115 14 167
Total  417 591 7 197 224 35 0 33 94 28 71 125 21 173
D
  + − + − + − + − + − + − + −
IgM + 113 56 0 1 70 14 0 2 24 15 15 19 4 5
 − 276 563 5 198 143 32 1 30 66 17 47 115 14 171
Total  389 619 5 199 213 46 1 32 90 32 62 134 18 176
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Positivity	 for	aCL	and	aβ2GPI	antibodies	did	not	predict	adverse	








clinical	manifestations	of	APS.9,33‐35	However,	 previous	 reports	 on	
the	 association	 between	 aPL	 titers	 and	 pregnancy	 morbidity	 are	
conflicting.32,36,37	In	a	retrospective	study	a	higher	cut‐off	value	did	








results	 showed	 that	 IgM	 titers	were	not	 significantly	 different	 be‐
tween	obstetrical	patients	and	our	control	population.	Of	note,	the	
maximum	 IgM	titer	measured	 in	obstetric	patients	was	 lower	 than	













TA B L E  5  Additional	value	of	aCL	and	aβ2GPI	IgM	antibodies	in	thrombosis






n = 350 
2.8	(2.1‐3.7)





































TA B L E  6  Additional	value	of	aCL	and	aβ2GPI	IgM	antibodies	in	pregnancy	morbidity



















































bidity,	 combined	 positivity	 for	 LAC	 and	 IgG	 or	 positivity	 for	 LAC	




Diagnosis	of	APS	 is	dependent	on	 laboratory	 tests	detecting	
aPL	 antibodies.10,14,40	 Currently	 no	 gold	 standard	 exists	 for	 the	
detection	of	 aPL	antibodies.	 Solid	phase	assays	 are	poorly	 stan‐
dardized	and	many	studies	have	shown	that	different	results	are	
obtained	by	measuring	the	same	sample.10,14	 In	addition,	studies	
have	 shown	 that	 solid	 phase	 assays	 are	 associated	 with	 a	 large	
inter‐laboratory	variation.10,41	 In	order	 to	be	 independent	of	 the	
solid	phase	assay	used	and	minimize	the	interlaboratory	and	inter‐
individual	variation	in	aPL	detection,	a	single	operator	performed	
all	 assays	 within	 one	 laboratory.	 Although	 we	 demonstrated	 a	
largely	 similar	 clinical	 performance	 for	 all	 platforms,	 these	 data	
indicate	that	results	for	single	parameters	may	vary	between	plat‐





and	 IgM	 showed	 higher	 variation	 of	 OR	 among	 the	 solid	 phase	
assays.	Combined	positivity	for	LAC,	IgG	and	IgM	aCL	or	aβ2GPI	
antibodies	was	highly	associated	with	thrombosis	and	pregnancy	
morbidity.	 However,	 calculated	 OR	 varied	 strongly	 among	 solid	
phase	assays,	accompanied	with	wide	95%	confidence	intervals.
In	conclusion,	 in	a	large	multicenter	study	aCL	and	aβ2GPI	IgM	
antibodies	 were	 significantly	 correlated	 with	 clinical	 features	 of	
APS.	However,	IgM	is	only	independently	associated	with	pregnancy	
morbidity	and	not	with	thrombosis.	Altogether,	our	data	support	the	
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J.M.,	 and	D.W.	collected	 samples	and	 identified	 sample	character‐
istics.	Samples	were	analyzed	under	supervision	of	K.M.J.D.	W.C.,	






Persistently positive for at







aCL IgM or aβ2GPI IgM
aβ2GPI IgM
testing not advised






*In agreement with the SSC guidelines1
aCL, anti-cardiolipin
aβ2GPI, anti-β2glycoprotein I
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